Health and Healthcare

T2 Biosystems Prices Secondary Offering

Thinkstock

T2 Biosystems Inc. (NASDAQ: TTOO) saw its shares drop handily early on Friday after the firm announced that it would be pricing its secondary offering. The company is offering 4.375 million shares at $4 apiece, with an overallotment option for an additional 656,250 shares. At this price the entire offering is valued up to $20.125 million.

Keep in mind that before the move the total market cap of this company was roughly $187 million.

The underwriters for this offering are Canaccord Genuity, Cantor Fitzgerald, Janney Montgomery Scott, Jones Trading and WBB.

This is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The company is using its T2 Magnetic Resonance technology (T2MR) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of health care by helping medical professionals make targeted treatment decisions earlier.

T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and it can detect cellular targets at limits of detection as low as one colony forming unit per milliliter. Its initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.

The company intends to use the net proceeds of this offering to fund commercial efforts and research and development activities and for other general corporate and working capital purposes. Management believes that its cash, cash equivalents and short-term investments, together with the net proceeds from this offering, will fund its operations into the first half of 2019.

Shares of T2 were last seen down about 25% at $4.55, with a consensus analyst price target of $5.00 and a 52-week range of $2.50 to $8.04.

The #1 Thing to Do Before You Claim Social Security (Sponsor)

Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.

A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.